Dr. Gorelick is board-certified in psychiatry and addiction medicine and a Distinguished Life Fellow of the American Psychiatric Association. He has more than 35 years of clinical and clinical research experience in the fields of addiction psychiatry, addiction medicine, and clinical pharmacology, resulting in publication of more than 190 peer-reviewed scientific articles, authorship/co-authorship of more than 50 book chapters, and invited presentations at national and international scientific meetings. He has led inpatient and outpatient addiction treatment programs and designed, conducted, and analyzed phase I and phase II controlled clinical trials.
Dr. Gorelick's research interests are the clinical pharmacology of substance abuse, substance withdrawal, and development of new biological treatments for substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation (TMS). His recent work focuses on cannabis (marijuana) and the cannabinoid chemicals found in the plant (including their potential therapeutic uses), new medications to treat alcohol and cocaine abuse, and treatment of individuals with both substance use disorders and a comorbid major psychiatric disorder, such as schizophrenia. Dr. Gorelick is Scientific Director of the Department's Clinical Neurobehavioral Center, where he is conducting outpatient studies of new medication to treat alcohol use disorder.
Dr. Gorelick has an interest in the ethics of clinical research, serving for 10 years as chair of an Institutional Review Board (IRB) that reviewed human research studies, and as a member of the NIH Human Subjects Research Advisory Committee and the NIH Committee on Scientific Conduct and Ethics.
Clinical pharmacology of substance abuse, substance withdrawal, and biological treatments of substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation (TMS). Current focus is on cannabis (marijuana), alcohol, and tobacco.
Dr. Gorelick specializes in addiction psychiatry and addiction medicine.